Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Jianan Bao, Ling Zhou, Mengying Xu & Jingjing Ma. (2023) The impact of pharmacist intervention on the intravenous-to-oral switch therapy of proton pump inhibitors in cardiovascular surgery. Expert Opinion on Drug Safety 22:7, pages 611-619.
Read now
Read now
Jerome R Lechien. (2022) Treating and Managing Laryngopharyngeal Reflux Disease in the Over 65s: Evidence to Date. Clinical Interventions in Aging 17, pages 1625-1633.
Read now
Read now
Valeria Dipasquale, Giuseppe Cicala, Francesca Laganà, Paola Cutroneo, Patrizia Felicetti, Simona Potenza, Giuseppe Trimarchi, Edoardo Spina & Claudio Romano. (2022) Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data. Expert Opinion on Drug Safety 21:1, pages 127-132.
Read now
Read now
Nicolas Chapelle, Ines Ben Ghezala, Alan Barkun & Marc Bardou. (2021) The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opinion on Pharmacotherapy 22:2, pages 219-227.
Read now
Read now
Articles from other publishers (36)
Florence Carrouel, Mikhail Dziadzko, Charles Grégoire, Michel Galinski, Claude Dussart & Virginie-Eve Lvovschi. (2023) Relevance of early management by proton-pump inhibitor in acute upper gastro-intestinal tract disorder: A scoping review. Biomedicine & Pharmacotherapy 167, pages 115523.
Crossref
Crossref
Jerome R. Lechien. (2023) Personalized Treatments Based on Laryngopharyngeal Reflux Patient Profiles: A Narrative Review. Journal of Personalized Medicine 13:11, pages 1567.
Crossref
Crossref
Marie Verhasselt, Alejandra Rodriguez, Didier Dequanter & Jerome R Lechien. (2023) Chronic Course, Weaning, and Awareness of Patients With Reflux Toward Proton Pump Inhibitor Therapy. Journal of Voice 37:4, pages 578-585.
Crossref
Crossref
Amber N. Edinoff, Natalie W. Wu, Katelyn Parker, Edwin Dudossat, Lauren Linquest, Chelsi J. Flanagan, Anam Dharani, Hirni Patel, Olga Willett, Elyse M. Cornett, Adam M. Kaye & Alan D. Kaye. (2023) Proton Pump Inhibitors, Kidney Damage, and Mortality: An Updated Narrative Review. Advances in Therapy 40:6, pages 2693-2709.
Crossref
Crossref
Giammarco Baiardi, Giulia Calvini, Serena Panarello, Chiara Fioravanti, Manuela Stella, Antonietta Martelli, Giancarlo Antonucci & Francesca Mattioli. (2023) Prescriptive Appropriateness: Inhospital Adherence to Proton Pump Inhibitors Deprescription Flow Chart. Pharmaceuticals 16:5, pages 635.
Crossref
Crossref
Miguel Del-Pino & Emilio J. Sanz. (2023) Analysis of deprescription strategies of proton pump inhibitors in primary care: a narrative review. Primary Health Care Research & Development 24.
Crossref
Crossref
Lu Liu, Yongqi Yu, Qingze Fan, Zhigui Wu, Xiuying Li & Hongli Luo. (2022) Impact of proton pump inhibitor management committee’s multifaceted interventions on acid suppressant prescribing patterns in outpatient and emergency departments. BMC Health Services Research 22:1.
Crossref
Crossref
Man-Li Zhang, Yu-Xin Fan, Rui Meng, Wen-Ke Cai, Sun-Jun Yin, Tao Zhou, Yan-Hua Huang, Ping Wang, Fang-Fang Jiang, Mei Yang & Gong-Hao He. (2022) Proton Pump Inhibitors and Cancer Risk. American Journal of Clinical Oncology 45:11, pages 475-485.
Crossref
Crossref
Michael Hughes, Yannick Allanore, Murray Baron, Francesco Del Galdo, Christopher P Denton, Tracy Frech, Daniel E Furst, Ilaria Galetti, Lorenzo Dagna, Ariane L Herrick, Masataka Kuwana, Pietro Matucci-Cerinic, Zsuzsanna H McMahan, Charles D Murray, Susanna Proudman & Marco Matucci-Cerinic. (2022) Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease. The Lancet Rheumatology 4:11, pages e795-e803.
Crossref
Crossref
Da Hyun Jung. (2022) Association of Long-term Use of Proton Pump Inhibitors with Mortality. The Korean Journal of Gastroenterology 80:4, pages 203-205.
Crossref
Crossref
Chun-Han Lo, Peiyun Ni, Yan Yan, Wenjie Ma, Amit D. Joshi, Long H. Nguyen, Raaj S. Mehta, Paul Lochhead, Mingyang Song, Gary C. Curhan, Yin Cao & Andrew T. Chan. (2022) Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality. Gastroenterology 163:4, pages 852-861.e2.
Crossref
Crossref
Annelies van Vuren, Jean Louis Kerkhoffs, Saskia Schols, Anita Rijneveld, Erfan Nur, Dore Peereboom, Yves Gandon, Paco Welsing, Richard van Wijk, Roger Schutgens, Wouter van Solinge, Joannes Marx, Tim Leiner, Bart Biemond & Eduard van Beers. (2022)
Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase
III
placebo‐controlled randomized cross‐over clinical trial
. American Journal of Hematology 97:7, pages 924-932.
Crossref
Crossref
Luis Garegnani, Camila Micaela Escobar Liquitay, Miguel Puga-Tejada & Juan VA Franco. (2022) Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia. Cochrane Database of Systematic Reviews 2022:5.
Crossref
Crossref
Yuan-Hui Liu, Zhi-Yuan Cao, Yi-Ning Dai, Li-Huan Zeng, Ye-Shen Zhang, Hua-Lin Fan, Chong-Yang Duan, Ning Tan & Peng-Cheng He. (2022) Association of Proton Pump Inhibitor and Infection and Major Adverse Clinical Events in Patients With ST-Elevation Myocardial Infarction: A Propensity Score Matching Analysis. Frontiers in Medicine 9.
Crossref
Crossref
Sajesh K. Veettil, Saranrat Sadoyu, Elizabeth M Bald, Viji P. Chandran, Scott Anh Tuan Khuu, Panitan Pitak, Yeong Yeh Lee, Athira Balakrishnan Nair, Paul T. Antony, Alexander C. Ford & Nathorn Chaiyakunapruk. (2021) Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials. British Journal of Clinical Pharmacology 88:4, pages 1551-1566.
Crossref
Crossref
Francisco Mesonero, Cristina Fernández, Eugenia Sánchez-Rodríguez, Ana García-García Paredes, Carla Senosiain, Agustín Albillos & Antonio López-Sanromán. (2022) Polypharmacy in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 56:3, pages e189-e195.
Crossref
Crossref
E. Fuentes-Valenzuela, P. Díez Redondo, J. Tejedor-Tejada, R. Nájera-Muñoz, L. Sánchez-Delgado & C. Maroto-Martín. (2022) Tratamiento con inhibidores de la bomba de protones. ¿Realmente lo necesita el paciente?. Medicina de Familia. SEMERGEN 48:2, pages 82-87.
Crossref
Crossref
O. D. Lopina, B. K. Nurgalieva & T. L. Lapina. (2021) Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole. Russian Journal of Gastroenterology, Hepatology, Coloproctology 31:4, pages 55-63.
Crossref
Crossref
Ivy N. Haskins, Megan E. Lombardi, David Wayne Overby & Timothy M. Farrell. (2021) The Endoscopic Management of Achalasia: Less May Lead to More. The American Surgeon 87:12, pages 1953-1955.
Crossref
Crossref
Lamuela L. J. Calvo, P. García Cámara, M. Llorente Barrio, O. Sierra Gabarda, R. Monzón Baez, J. M. Arbonés Mainar, J. Alcedo González & V. Bernal Monterde. (2021) Successful deprescribing of proton pump inhibitors with a patient-centered process: the DESPIBP Project. European Journal of Clinical Pharmacology 77:12, pages 1927-1933.
Crossref
Crossref
Vered Rosenberg, Roie Tzadok, Gabriel Chodick & Revital Kariv. (2021) Proton pump inhibitors long term use‐trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiology and Drug Safety 30:11, pages 1576-1587.
Crossref
Crossref
Kai-Hong Yi & Xue-Rui Tan. (2021) Advances in prevention and treatment of digestive tract damage induced by antithrombotic therapy with traditional Chinese and Western medicine. World Chinese Journal of Digestology 29:19, pages 1089-1095.
Crossref
Crossref
M. J. Domper Arnal, S. García Mateo, S. Hermoso-Durán, D. Abad, P. Carrera-Lasfuentes, A. Velazquez-Campoy, O. Abian Franco & A. Lanas. (2021) False-positive fecal immunochemical test results in colorectal cancer screening and gastrointestinal drug use. International Journal of Colorectal Disease 36:9, pages 1861-1869.
Crossref
Crossref
Chen Chen, Hui Liu, Ruqiao Duan, Fangfang Wang & Liping Duan. (2021) The efficacy and safety of acid suppressants for gastrointestinal bleeding prophylaxis in cardiac care unit patients. Journal of Gastroenterology and Hepatology 36:8, pages 2131-2140.
Crossref
Crossref
Mary E Phillips, Andrew D Hopper, John S Leeds, Keith J Roberts, Laura McGeeney, Sinead N Duggan & Rajesh Kumar. (2021) Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterology 8:1, pages e000643.
Crossref
Crossref
G.M. Saiz Ladera, M.E. Pejenaute Labari & J.N. García Pascual. (2021) Actualización en la prescripción de inhibidores de la bomba de protones. Qué hacer y qué no hacer. Medicina de Familia. SEMERGEN 47:4, pages 267-279.
Crossref
Crossref
Fernanda Cristina Stenger Moura, Valdir Cechinel-Filho, Francesco Antonio Greco, Larissa Venzon, Mariane Caroline Meurer, Tauani Caroline dos Santos França, Bruna Longo, Lincon Bordignon Somensi, Luisa Nathalia Bolda Mariano, Alexandre Bella Cruz, Antonio Macchiarulo, Aurélie Schoubben, Maurizio Ricci, Tania Mari Belle Bresolin & Luisa Mota da Silva. (2021) Taxifolin and gastro-adhesive microparticles containing taxifolin promotes gastric healing in vivo, inhibits Helicobacter pylori in vitro and proton pump reversibly in silico. Chemico-Biological Interactions 339, pages 109445.
Crossref
Crossref
Angel Lanas. (2021) Proton Pump Inhibitor (PPI) co-therapy and gastrointestinal bleeding with antithrombotic drugs: a step forward but not enough. European Journal of Internal Medicine 85, pages 23-24.
Crossref
Crossref
Zhaoshi Bai, Nianyang Ding, Jianjuan Ge, Yue Wang, Lei Wang, Nan Wu, Qing Wei, Silu Xu, Xiaolin Liu & Guoren Zhou. (2020) Esomeprazole overcomes paclitaxel‐resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells. Cell Biology International 45:1, pages 177-187.
Crossref
Crossref
Mohamed Ben‐Eltriki, Carolyn J. Green, Malcolm Maclure, Vijaya Musini, Ken L. Bassett & James M. Wright. (2020) Do proton pump inhibitors increase mortality? A systematic review and in‐depth analysis of the evidence. Pharmacology Research & Perspectives 8:5.
Crossref
Crossref
Naw May Pearl Cartee & Michael M. Wang. (2020) Binding of omeprazole to protein targets identified by monoclonal antibodies. PLOS ONE 15:9, pages e0239464.
Crossref
Crossref
Mária Matuz, Ria Benkő, Zsófia Engi, Krisztina Schváb, Péter Doró, Réka Viola, Mária Szabó & Gyöngyvér Soós. (2020) Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Frontiers in Pharmacology 11.
Crossref
Crossref
Yeliz ŞAHİNER, Cihangir DOĞU, Serhat ÖZÇİFTÇİ, Güvenç DOĞAN, Özgür YAĞAN & Emre DEMİR. (2020) YOĞUN BAKIM HASTALARINDA BESLENME İNTOLERANSINA ETKİ EDEN FAKTÖRLER VE MORTALİTE İLE İLİŞKİSİ: PROSPEKTİF GÖZLEMSEL KLİNİK ARAŞTIRMAFactors Affecting Nutrition Intolerance in Intensive Care Patients and Their Relationship with Mortality: A Prospective Observational Clinical Research. Kırıkkale Üniversitesi Tıp Fakültesi Dergisi 22:1, pages 20-29.
Crossref
Crossref
Shih-Wei LaiKuan-Fu Liao. (2020) Association Between Proton Pump Inhibitors Use and Dementia Risk. American Journal of Gastroenterology 115:4, pages 631-631.
Crossref
Crossref
Paulien Vinke, Evertine Wesselink, Wout van Orten-Luiten & Klaske van Norren. (2020) The Use of Proton Pump Inhibitors May Increase Symptoms of Muscle Function Loss in Patients with Chronic Illnesses. International Journal of Molecular Sciences 21:1, pages 323.
Crossref
Crossref
Marco G. PattiFrancisco SchlottmannFernando A. Herbella. (2020) The Treatment of Esophageal Achalasia: At the Intersection Between Innovation and Patient's Care. Journal of Laparoendoscopic & Advanced Surgical Techniques.
Crossref
Crossref